TNX-1300 (Injection) + Placebo (Injection)
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cocaine Use
Conditions
Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse, Cocaine Adverse Reaction
Trial Timeline
Aug 16, 2024 → Apr 21, 2025
NCT ID
NCT06045793About TNX-1300 (Injection) + Placebo (Injection)
TNX-1300 (Injection) + Placebo (Injection) is a phase 2 stage product being developed by Tonix Pharmaceuticals for Cocaine Use. The current trial status is terminated. This product is registered under clinical trial identifier NCT06045793. Target conditions include Cocaine Use, Cocaine Intoxication, Cocaine Toxicity.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06045793 | Phase 2 | Terminated |
Competing Products
13 competing products in Cocaine Use
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy | Johnson & Johnson | Phase 3 | 77 |
| Topiramate | Johnson & Johnson | Phase 2 | 52 |
| quetiapine | AstraZeneca | Approved | 85 |
| quetiapine fumarate + Matched Placebo | AstraZeneca | Pre-clinical | 23 |
| AFQ056 + Placebo | Novartis | Phase 1 | 33 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| ALKS 33-BUP + ALKS 33 + Placebo | Alkermes | Phase 1 | 30 |
| VIVITROL (Naltrexone extended-release injectable suspension) + Placebo | Alkermes | Phase 2 | 49 |
| vigabatrin + placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| Vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2/3 | 60 |
| Vigabatrin + Placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| CPP-115 + Placebo | Catalyst Pharmaceuticals | Phase 1 | 28 |
| TNX-1300 | Tonix Pharmaceuticals | Phase 2 | 44 |